# Bexobrutideg

Source: https://onco.cc/drugs/bexobrutideg/  
OnCo record `bexobrutideg` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bexobrutideg is an experimental protein degrader from Nurix Therapeutics in phase 3 trials for chronic lymphocytic leukaemia, aimed at BTK (Bruton tyrosine kinase).

## Summary

Bexobrutideg (NX-5948) is a protein degrader developed by Nurix Therapeutics. Its target is BTK (Bruton tyrosine kinase) (the sponsor names BTK (Bruton's tyrosine kinase)). The sponsor states: NX-5948 is an oral, CNS-penetrant BTK degrader that removes the BTK protein rather than only inhibiting its activity, which the sponsor states may help overcome kinase-domain and scaffolding-mediated resistance mutations. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07516093 (Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL), in chronic lymphocytic leukaemia. The largest, NCT07516093, plans to enrol 620 participants with primary completion expected 2029-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: NX-5948
- Modality: protein degrader
- Mechanism: NX-5948 is an oral, CNS-penetrant BTK degrader that removes the BTK protein rather than only inhibiting its activity, which the sponsor states may help overcome kinase-domain and scaffolding-mediated resistance mutations.

## Sources

- ClinicalTrials.gov: trials of Bexobrutideg: https://clinicaltrials.gov/search?intr=Bexobrutideg
- Sponsor pipeline page: https://www.nurixtx.com/pipeline/

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- targets: [BTK (Bruton tyrosine kinase)](https://onco.cc/targets/btk/)
- companies: [Nurix Therapeutics](https://onco.cc/companies/nurix/)
- trials: [A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)](https://onco.cc/trials/nct07221500/), [Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies](https://onco.cc/trials/nct07520006/), [Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL](https://onco.cc/trials/nct07516093/)

---
JSON: https://onco.cc/api/v1/entities/bexobrutideg.json